232 related articles for article (PubMed ID: 33008494)
1. Harnessing Natural Killer Cell Function for Genitourinary Cancers.
Bhardwaj N; Farkas AM; Gul Z; Sfakianos JP
Urol Clin North Am; 2020 Nov; 47(4):433-442. PubMed ID: 33008494
[TBL] [Abstract][Full Text] [Related]
2. Novel immunotherapies in GU malignancies.
Drakaki A; McDermott DF
Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
[TBL] [Abstract][Full Text] [Related]
3. An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy in uropathology].
Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen in patients with urologic cancers.
Guinan P; Ablin RJ; Barakat H; John T; Sadoughi N; Bush IM
Urol Res; 1973 Oct; 1(3):101-5. PubMed ID: 4804082
[No Abstract] [Full Text] [Related]
6. [The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].
Fukasawa K
Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):239-45. PubMed ID: 3226000
[No Abstract] [Full Text] [Related]
7. [Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell activity and proliferation of tumor cells].
Hayakawa M; Marumo K; Nagakura K; Hata M; Fujioka T; Nakamura H; Murai M
Nihon Hinyokika Gakkai Zasshi; 1984 Jul; 75(7):1124-33. PubMed ID: 6542157
[No Abstract] [Full Text] [Related]
8. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
10. [Combination radiotherapy-immunotherapy in genitourinary cancer].
Ollivier L; Guimas V; Rio E; Vaugier L; Masson I; Libois V; Labbé M; Fradin D; Potiron V; Supiot S
Cancer Radiother; 2021 Oct; 25(6-7):565-569. PubMed ID: 34391648
[TBL] [Abstract][Full Text] [Related]
11. Latest progress in molecular biology and treatment in genitourinary tumours.
González-Del-Alba A; Arranz JÁ; Bellmunt J; Maroto JP; Fernández-Calvo O; Valderrama BP; González-Billalabeitia E; Méndez-Vidal MJ; Cassinello J; Romero-Laorden N; Climent MÁ; Puente J; Peláez I; Lázaro-Quintela M; Gallardo E; Suárez C
Clin Transl Oncol; 2020 Dec; 22(12):2175-2195. PubMed ID: 32440915
[TBL] [Abstract][Full Text] [Related]
12. Immunology of genitourinary tumors.
Guinan P; Sadoughi N; Bush IM; John T; Eghrari F; Ablin RJ
Urology; 1973 Nov; 2(5):493-9. PubMed ID: 4131868
[No Abstract] [Full Text] [Related]
13. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in genitourinary neoplasia.
Droller MJ
J Urol; 1985 Jan; 133(1):1-5. PubMed ID: 2578065
[No Abstract] [Full Text] [Related]
15. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
16. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
[TBL] [Abstract][Full Text] [Related]
17. [DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].
Hegele A; Heinzer H; Rüttinger D; Siebels M
Aktuelle Urol; 2012 Jul; 43(4):219-26. PubMed ID: 23035262
[TBL] [Abstract][Full Text] [Related]
18. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer.
Elhilali MM; Brosman SA; Vescera C; Paul JG; Fahey JL
Cancer; 1978 May; 41(5):1765-70. PubMed ID: 647626
[No Abstract] [Full Text] [Related]
19. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
20. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
